Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MetroWILMS-1906 metronomic chemotherapy for relapsed or refractory Wilms tumor
2022-502687-20-00Phase 2Authorised
- Sponsor
- Centre Oscar Lambret
- Start
- Sep 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinblastine, isotretinoin, temozolomide, etoposide, irinotecan and 1 more in Wilms' tumor, sponsored by Centre Oscar Lambret. Primary endpoints: Dose-limiting toxicity and Disease control after 2 cycles. Planned start Sep 2022; status: authorised.
02
Drugs
vinblastineisotretinointemozolomideetoposideirinotecan
03
Conditions
Wilms' tumor
Beyond the preview
Go deeper on 2022-502687-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502687-20-00.